Biogen Announces $5 Billion Share Repurchase Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) today announced that its Board of Directors has authorized a program to repurchase up to $5 billion of the Company’s common stock. The share...
View ArticleBiogen Names Matt Griffiths as Chief Information Officer
Former Dell Executive to Advance Biogen’s Focus on Technology, Data and Devices CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the appointment of Matt Griffiths as senior...
View ArticleBiogen to Present at the 2015 UBS Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 2015 UBS Global Healthcare Conference. The webcast will be live on Tuesday, May 19, 2015 at...
View ArticleBiogen to Present at Bernstein’s 31st Annual Strategic Decisions Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that it will present at Bernstein’s 31st Annual Strategic Decisions Conference. The webcast will be live on Wednesday, May...
View ArticleBiogen 2015 Annual Shareholder Meeting Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that its 2015 Annual Shareholder Meeting will be webcast live on Wednesday, June 10, 2015 at 9:00 a.m. ET. To access the...
View ArticleBiogen and Samsung Bioepis Announce New Data for Three Anti-TNF Biosimilar...
SB4 and SB2 biosimilar candidates demonstrated Phase III clinical comparability to respective reference products, etanercept (Enbrel®) and infliximab (Remicade®) Pharmacokinetic equivalence data for...
View ArticleNew Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study...
- Full Results from ALPROLIX® Pediatric Study to Be Released For the First Time - - Interim Findings to be Presented from ASPIRE, a Long-Term Extension Study with ELOCTATE® in Adults and Children with...
View ArticleBiogen Achieves Carbon Neutrality
Company increases global environmental leadership; new citizenship report highlights continued commitment to sustainability, philanthropy and diversity CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen...
View ArticleBiogen and Sobi Announce European Medicines Agency Validates ALPROLIX®...
CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has accepted...
View ArticleBiogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology
Companies to advance a potentially transformative treatment approach for genetic diseases of the eye AGTC to receive $124M upfront, with potential future milestone payments and royalties AGTC to host...
View ArticleBiogen to Report Second Quarter 2015 Financial Results on July 24, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2015 financial results on Friday, July 24, 2015, before the financial markets open. Language:...
View ArticleDouglas Williams to Leave Biogen for Biotechnology Start-Up
Alfred Sandrock, M.D., Ph.D., and Spyros Artavanis-Tsakonas, Ph.D., will lead Biogen R&D CAMBRIDGE, Mass.--(BUSINESS WIRE)--Douglas Williams, Ph.D., will leave Biogen (NASDAQ: BIIB) at the end of...
View ArticleBiogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s...
Results Demonstrate Statistically Significant Reduction of Beta Amyloid, Dose-Dependent Slowing of Clinical Decline and Acceptable Safety CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Biogen (NASDAQ: BIIB)...
View ArticleBiogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion
TECFIDERA® now the most prescribed oral MS therapy globally Sites initiated for aducanumab Phase 3 studies for Alzheimer’s disease CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today...
View ArticleBiogen Enters Collaboration with the Parkinson’s Institute and Clinical Center
Collaboration aims to enhance disease understanding and increase the pace of discovery of new therapeutics CAMBRIDGE, Mass. & SUNNYVALE, Calif.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) and the...
View ArticleExtension Study Data Supporting Long-Term Safety and Efficacy of Eloctate®...
– Interim Results Show Participants Maintained Low Bleeding Rates with Prophylactic Dosing – CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Newly published clinical data demonstrate that people on...
View ArticleResults from B-YOND Extension Study Reinforce Long-Term Clinical Profile of...
Interim Data Presented at NHF Annual Meeting Show ALPROLIX Maintained Low Bleeding Rates with Prophylactic Infusions One to Two Weeks Apart DALLAS--(BUSINESS WIRE)--New clinical data support the...
View ArticleBiogen, the ALS Association and Columbia University Medical Center...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB), the ALS Association and Columbia University Medical Center (CUMC) today announced a new collaboration to better understand the differences and...
View ArticleUSPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for...
Today Biogen (NASDAQ: BIIB) announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) declined to institute an inter partes review of U.S. Patent...
View ArticleBiogen Enrolls First Patient in Global Phase 3 Study of Investigational...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today that the first patient has been enrolled in the Phase 3 clinical program for its investigational treatment aducanumab. The Phase...
View Article
More Pages to Explore .....